 "Lupin gains on tentative approval for generic Epzicom tablets")
Lupin gained 4% to Rs 1,470 on the National Stock Exchange (NSE) after the company announced that it received tentative approval for generic Epzicom tablets.
“The company has received tentative approval for its Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg from the United State Food and Drug Administration (USFDA) to market a generic version of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg,” Lupin said in a press release.
Lupin’s Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Epzicom tablets had US sales of $426 million, according to IMS Mat September 2016.
At 12:30 pm, the stock was up 3.5% at Rs 1,463 on the NSE as compared to 0.02% rise in the Nifty50 index. A combined 773,774 shares changed hands on the counter on BSE and NSE so far.
“The company has received tentative approval for its Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg from the United State Food and Drug Administration (USFDA) to market a generic version of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg,” Lupin said in a press release.
Lupin’s Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Epzicom tablets had US sales of $426 million, according to IMS Mat September 2016.
At 12:30 pm, the stock was up 3.5% at Rs 1,463 on the NSE as compared to 0.02% rise in the Nifty50 index. A combined 773,774 shares changed hands on the counter on BSE and NSE so far.